FHTX logo

FHTX
Foghorn Therapeutics Inc

632
Mkt Cap
$247.77M
Volume
164,706.00
52W High
$6.95
52W Low
$3.27
PE Ratio
-3.50
FHTX Fundamentals
Price
$4.22
Prev Close
$4.16
Open
$4.15
50D MA
$4.72
Beta
1.89
Avg. Volume
125,756.55
EPS (Annual)
-$1.18
P/B
-3.24
Rev/Employee
$291,594.34
$221.22
Loading...
Loading...
News
all
press releases
CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
News Placeholder
More News
News Placeholder
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Lags Revenue Estimates
Foghorn Therapeutics (FHTX) delivered earnings and revenue surprises of -3.57% and -64.62%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Top Estimates
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of +253.07% and +56.20%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Foghorn Therapeutics Inc. (FHTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Foghorn Therapeutics (FHTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
News Placeholder
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Tops Revenue Estimates
Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of +3.04% and +5.43%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Given Average Recommendation of "Moderate Buy" by Brokerages
Foghorn Therapeutics Inc. (NASDAQ:FHTX - Get Free Report) has earned an average recommendation of "Moderate Buy" from the nine ratings firms that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, seven have given a buy recommen...
News Placeholder
Foghorn Therapeutics (NASDAQ:FHTX) Stock Price Down 1.9% - Time to Sell?
Foghorn Therapeutics (NASDAQ:FHTX) Stock Price Down 1.9% - Here's What Happened...
News Placeholder
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Consensus Rating of "Moderate Buy" from Brokerages
Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX - Get Free Report) have earned an average rating of "Moderate Buy" from the ten ratings firms that are currently covering the firm, Marketbeat...
News Placeholder
Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.6% Jump Turn into More Strength?
Dianthus Therapeutics, Inc. (DNTH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
News Placeholder
What is HC Wainwright's Forecast for FHTX FY2026 Earnings?
Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) - HC Wainwright boosted their FY2026 earnings per share (EPS) estimates for Foghorn Therapeutics in a report released on Thursday, March 12th. HC...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available